lemilvo 15 mg
actavis ltd. - malta - aripiprazolum - compr. - 15mg - antipsihotice alte antipsihotice
quetiapina teva 150 mg
teva pharm. works private ltd. company - ungaria - quetiapinum - compr. cu elib. prel. - 150mg - antipsihotice diazepine, oxazepine si tiazepine
quetiapina teva 200 mg
teva pharm. works private ltd. company - ungaria - quetiapinum - compr. cu elib. prel. - 200mg - antipsihotice diazepine, oxazepine si tiazepine
quetiapina teva 300 mg
teva pharm. works private ltd. company - ungaria - quetiapinum - compr. cu elib. prel. - 300mg - antipsihotice diazepine, oxazepine si tiazepine
quetiapina teva 400 mg
teva pharm. works private ltd. company - ungaria - quetiapinum - compr. cu elib. prel. - 400mg - antipsihotice diazepine, oxazepine si tiazepine
quetiapina teva 50 mg
teva pharm. works private ltd. company - ungaria - quetiapinum - compr. cu elib. prel. - 50mg - antipsihotice diazepine, oxazepine si tiazepine
valganciclovir teva 450 mg
teva gyogyszergyar zrt.(teva pharm. works private) - ungaria - valganciclovirum - compr. film. - 450mg - antivirale cu actiune directa nucleozide si nucleotide excl inhibitori reverstranscriptaza
ivergen premium l.a.
dopharma vet , romania - ivermectină - soluţie injectabilă - antiparazitare - bovine, ovine, porcine - bovine, porcine și ovine tratamentul parazitozelor interne și externe.
raxone
chiesi farmaceutici s.p.a - idebenonă - atrofia optică, ereditară, leber - alte psihostimulante și nootropics, psychoanaleptics, - raxone este indicat pentru tratamentul insuficienței vizuale la adolescenți și pacienți adulți cu neuropatia optică ereditară leber (lhon).
tysabri
biogen netherlands b.v. - natalizumab - scleroză multiplă - imunosupresoare selective - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.